GlassScriptPhysician profile
Marjon Vatanchi
NPI 1073951109
$37,724.18
in general payments reported to CMS, 2019-2025
31 companies · $10K in 2025
The $10K reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $16.76 · 2021: $139 · 2022: $1,552 · 2023: $4,936 · 2024: $20K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Consulting Fee: $11K · Food and Beverage: $5,455 · Travel and Lodging: $1,477 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,600.00 |
| Consulting Fee | $11,153.00 |
| Food and Beverage | $5,454.58 |
| Travel and Lodging | $1,476.88 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $19,520.19 | 2023-2025 | Aklief |
| Genzyme Corporation | $9,553.18 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $4,182.99 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Abbvie INC. | $829.47 | 2019-2025 | Skyrizi, Rinvoq |
| Incyte Corporation | $481.91 | 2022-2025 | Opzelura |
| Amgen INC. | $379.91 | 2022-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $297.71 | 2022-2023 | Tremfya |
| Merz North America, INC. | $296.56 | 2023 | Xeomin |
| Regeneron Healthcare Solutions, INC. | $279.85 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $239.31 | 2022-2025 | Tremfya, Remicade, Stelara |
| Dermavant Sciences, INC. | $231.00 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $159.01 | 2022-2023 | Sotyktu |
| Pfizer INC. | $156.63 | 2022-2024 | |
| Ucb, INC. | $146.62 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $144.24 | 2021-2024 | Taltz, Olumiant, Ebglyss |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $111.32 | 2025 | Simplimax, Cygnus Dual |
| Allergan, INC. | $97.33 | 2019 | |
| Leo Pharma INC. | $94.92 | 2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $78.53 | 2022-2023 | |
| Botanix Sb INC | $77.95 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.25 | 2024-2025 | Spevigo |
| Almirall LLC | $54.91 | 2025 | Seysara, Klisyri |
| Biofrontera INC. | $41.79 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $40.23 | 2023-2025 | Zoryve |
| Csl Behring | $32.80 | 2024 | Haegarda |
| Mayne Pharma Commercial LLC | $30.99 | 2025 | |
| Revance Therapeutics, INC. | $29.05 | 2025 | Daxxify |
| Celgene Corporation | $22.75 | 2019 | |
| Kyowa Kirin, INC. | $22.31 | 2023 | Poteligeo |
| Vyne Pharmaceuticals INC. | $16.76 | 2020 | |
| Verrica Pharmaceuticals INC. | $14.71 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marjon Vatanchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.